Anastrozole and Rosuvastatin Interaction: Avoid | Peptide Database

Join others researching Meldonium — share findings, ask questions, and learn from real experiences Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis. Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.

Join others researching Ketoconazole — share findings, ask questions, and learn from real experiences Ketoconazole is an FDA-approved azole antifungal that has gained widespread use as a topical adjunct in hair loss treatment. Available as a 1-2% medicated shampoo, ketoconazole disrupts DHT binding at the hair follicle and reduces scalp inflammation driven by the fungus Malassezia, both of which contribute to follicular miniaturization. It is a core component of the widely referenced "big 3" hair loss stack alongside finasteride and minoxidil. While ketoconazole was originally developed as a systemic antifungal for conditions like fungal infections and seborrheic dermatitis, its topical anti-androgenic properties at the scalp level have made it a practical and low-risk addition to hair loss regimens. When used as a shampoo, systemic absorption is negligible, keeping the side effect profile limited to occasional local irritation. Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and killing Malassezia fungi that colonize the scalp and contribute to inflammation and seborrheic dermatitis. This anti-inflammatory effect reduces the chronic follicular inflammation associated with androgenetic alopecia. Independently, ketoconazole has demonstrated topical anti-androgenic activity by disrupting the binding of dihydrotestosterone (DHT) and other androgens to receptors at the hair follicle. Some evidence also suggests it may interfere with local androgen synthesis pathways. Unlike systemic anti-androgens such as finasteride, ketoconazole shampoo exerts these effects locally at the scalp without meaningful systemic hormonal changes, making it a well-tolerated complement to oral DHT-blocking therapies.